Recent work on bispecific CD19/CD22-directed CAR-T cells demonstrated the potential of dual targeting approaches to enhance anti-tumor activity and efforts are underway to further advance multi-specific CAR targeting both in the pre-clinical and clinical settings (33, 34, 79, 81, 82). The gene discussed is CD19; the disease is neoplasm.